Dataset Information

Use of Immunohistochemistry to Determine Expression of Rab5 Subfamily of GTPases in Mature and Developmental Brains.

ABSTRACT: Rab GTPases are essentially molecular switches. They serve as master regulators in intracellular membrane trafficking from the formation and transport of vesicles at the originating organelle to its fusion to the membrane at the target organelle. Their functions are diversified and each has their specific subcellular location. Their expression may vary significantly in the same cell when the level of protein production is significantly different in different physiologic status. One of the best examples is the transition from fetal to mature status of cells. Expression and localization of Rab GTPases in mature and developing brains have not been well studied. Immunohistochemistry is an efficient way in the detection, semiquantitation, and localization of Rab GTPases in tissue sections. It is inexpensive and fast which allow efficient mass screening of many sections. In this chapter, we describe the immunohistochemical assay protocol for analyzing several Rab protein expressions of the Rab5 subfamily, including Rab5, Rab17, Rab22, and Rab31, in developmental (fetal) and mature human brains.

SUBMITTER: Kam KL

PROVIDER: S-EPMC8917831 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Use of Immunohistochemistry to Determine Expression of Rab5 Subfamily of GTPases in Mature and Developmental Brains.

Kam Kwok-Ling KL Parrack Paige P Banworth Marcellus M Aravindan Sheeja S Li Guangpu G Fung Kar-Ming KM

Methods in molecular biology (Clifton, N.J.) 20210101

Rab GTPases are essentially molecular switches. They serve as master regulators in intracellular membrane trafficking from the formation and transport of vesicles at the originating organelle to its fusion to the membrane at the target organelle. Their functions are diversified and each has their specific subcellular location. Their expression may vary significantly in the same cell when the level of protein production is significantly different in different physiologic status. One of the best e ...[more]

PMID: 34453724

Similar Datasets

Project description:BackgroundFor non-small cell lung cancer (NSCLC), treatment with pembrolizumab is limited to patients with tumours expressing PD-L1 assessed by immunohistochemistry (IHC) using the PD-L1 IHC 22C3 pharmDx (Dako, Inc.) companion diagnostic test, on the Dako Autostainer Link 48 (ASL48) platform. Optimised protocols are urgently needed for use of the 22C3 antibody concentrate to test PD-L1 expression on more widely available IHC autostainers.MethodsWe evaluated PD-L1 expression using the 22C3 antibody concentrate in the three main commercially available autostainers Dako ASL48, BenchMark ULTRA (Ventana Medical Systems, Inc.), and Bond-III (Leica Biosystems) and compared the staining results with the PD-L1 IHC 22C3 pharmDx kit on the Dako ASL48 platform. Several technical conditions for laboratory-developed tests (LDTs) were evaluated in tonsil specimens and a training set of three NSCLC samples. Optimised protocols were then validated in 120 NSCLC specimens.ResultsOptimised protocols were obtained on both the VENTANA BenchMark ULTRA and Dako ASL48 platforms. Significant expression of PD-L1 was obtained on tissue controls with the Leica Bond-III autostainer when high concentrations of the 22C3 antibody were used. It therefore was not tested on the 120 NSCLC specimens. An almost 100% concordance rate for dichotomized tumour proportion score (TPS) results was observed between TPS ratings using the 22C3 antibody concentrate on the Dako ASL48 and VENTANA BenchMark ULTRA platforms relative to the PD-L1 IHC 22C3 pharmDx kit on the Dako ASL48 platform. Interpathologist agreement was high on both LDTs and the PD-L1 IHC 22C3 pharmDx kit on the Dako ASL48 platform.ConclusionAvailability of standardized protocols for determining PD-L1 expression using the 22C3 antibody concentrate on the widely available Dako ASL48 and VENTANA BenchMark ULTRA IHC platforms will expand the number of laboratories able to determine eligibility of patients with NSCLC for treatment with pembrolizumab in a reliable and concordant manner.

Project description:We have used microarray technology to identify the transcriptional targets of Rho subfamily GTPases. This analysis indicated that murine fibroblasts transformed by these proteins show similar transcriptomal profiles. Functional annotation of the regulated genes indicate that Rho subfamily GTPases target a wide spectrum of biological functions, although loci encoding proteins linked to proliferation and DNA synthesis/transcription are up-regulated preferentially. Rho proteins promote four main networks of interacting proteins nucleated around E2F, c-Jun, c-Myc, and p53. Of those, E2F, c-Jun and c-Myc are essential for the maintenance of cell transformation. Inhibition of Rock, one of the main Rho GTPase targets, leads to small changes in the transcriptome of Rho-transformed cells. Rock inhibition decreases c-myc gene expression without affecting the E2F and c-Jun pathways. Loss-of-function studies demonstrate that c-Myc is important for the blockage of cell-contact inhibition rather than for promoting the proliferation of Rho-transformed cells. However, c-Myc overexpression does not bypass the inhibition of cell transformation induced by Rock blockage, indicating that c-Myc is essential, but not sufficient, for Rock-dependent transformation. These results reveal the complexity of the genetic program orchestrated by the Rho subfamily and pinpoint protein networks that mediate different aspects of the malignant phenotype of Rho-transformed cells Experiment Overall Design: In order to generate the cell clones used in this study, we took advantage of the oncogenic properties of the constitutively active versions (Q63L mutants) of Rho subfamily proteins when overexpressed in rodent fibroblasts (Schuebel et al., 1998). Based on this property, we transfected NIH3T3 cells with plasmids encoding the indicated versions of Rho subfamily proteins to obtain foci of transformed cells. Selected foci were picked, pooled, and used for the subsequent microarray experiments. Experiment Overall Design: To avoid the activation of genetic programs related to serum withdrawal or contact inhibition that may confound the detection of Rho-specific transcriptomal changes (Coller et al., 2006), we cultured the chosen cell lines and the parental NIH3T3 cells in the presence of serum and maintained them at confluency levels lower than 70% prior to RNA extraction. In addition, we isolated total RNAs from eight (in the case of NIH3T3 cells), seven (in the case of RhoAQ63L-transformed cells) and six (in the case of RhoBQ63L- and RhoCQ63L-transformed cells) independent cell cultures in order to make it possible a robust statistical treatment of the data obtained. Experiment Overall Design: three 10-cm diameter plates containing exponentially growing cultures of IMB11-1P (expressing RhoAQ63L) IMB11-2P (expressing RhoBQ63L), or IMB11-3P (expressing RhoCQ63L) cells were washed with PBS and their total cellular RNAs isolated using the RNeasy kit (Qiagen) according to the supplierâs specifications. The quantity and quality of the total RNAs obtained was determined using 6000 Nano Chips (Agilent Technologies). Total RNA samples (4 ug) were then processed for hybridization on MGU75Av2 microarrays (Affymetrix) using standard Affymetrix protocols at the CIC Genomics and Proteomics Facility (www.cicancer.org). Normalization, filtering and analysis of the raw data obtained from the microarrays was carried out with the Bioconductor software (www.bioconductor.com) using de ReadAffy package and the RMA application. The RMA algorithm was selected over the standard Affymetrix software because it provides a better precision in signal detection to achieve adequate normalization of multiple microarray hybridizations, especially in cases of low levels of gene expression (Bolstad et al., 2004; Gautier et al., 2004; Gentleman et al., 2004; Parrish & Spencer, 2004). We considered a gene to be differentially expressed when exhibiting a signal â¥ 100 and met the following criteria: in the case of the characterization of the transcriptome of Rho-transformed cells, we regarded a gene as common to all GTPases when: i) It showed a fold change â¥ 1.5 in at least two of the cell lines used. ii) The fold change in the third cell line was â¥ 1.0 and displayed a similar variation trend when compared to the other two cell lines (i.e., similar up-regulation or down-modulation in the three cell lines). iii) The fold change values in the three cell lines had always P values â¤ 0.01. We regarded a gene as common to only two GTPases when: i) It showed a fold change â¥ 1.5 in two the cell lines with P values â¤ 0.01. ii) The fold change in the third cell line was non-existent or, alternatively, had P values â¥ 0.01. We considered a gene as uniquely-regulated by a GTPase when: i) The fold change in the expression levels of is transcript in the cell line transformed by that GTPase was â¥ 1.5 with P value â¤ 0.01. ii) The fold change, if any, obtained in the other cell lines had P values â¥ 0.01. Statistical analyses were performed using F-statistics.

Dataset Information

Use of Immunohistochemistry to Determine Expression of Rab5 Subfamily of GTPases in Mature and Developmental Brains.

Publications

Use of Immunohistochemistry to Determine Expression of Rab5 Subfamily of GTPases in Mature and Developmental Brains.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets